Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Carboplatin 98 Cisplatin 95 pembrolizumab 91 Gemcitabine 81 Paclitaxel 79 Docetaxel 70 Capecitabine 64 Oxaliplatin 53 Fluorouracil 51 Specimen Handling 50 Magnetic Resonance Spectroscopy 49 Bevacizumab 49 Radiotherapy 48 Dexamethasone 45 Cyclophosphamide 45 Drug Therapy 39 Leucovorin 38 Doxorubicin 37 Pemetrexed 35 Irinotecan 34 Injections 30 Rituximab 29 Vincristine 28 Trastuzumab 26 Radiosurgery 26 Prednisone 26 Lenalidomide 25 Etoposide 25 130-nm albumin-bound paclitaxel 25 Radiation 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recruiting × copper dotatate CU-64 × Clear all

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡